Cargando…
4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy
Although considerable progress has been made in understanding how tumors evade immune surveillance, measures to counter the same have not kept pace with the advances made in designing effective strategies. 4-1BB (CD137; TNFRS9), an activation-induced costimulatory molecule, is an important regulator...
Autores principales: | Vinay, Dass S., Kwon, Byoung S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society for Biochemistry and Molecular Biology
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4163883/ https://www.ncbi.nlm.nih.gov/pubmed/24499671 http://dx.doi.org/10.5483/BMBRep.2014.47.3.283 |
Ejemplares similares
-
New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
por: Etxeberria, Iñaki, et al.
Publicado: (2020) -
Exposure of a Distinct PDCA-1(+) (CD317) B Cell Population to Agonistic Anti-4-1BB (CD137) Inhibits T and B Cell Responses Both In Vitro and In Vivo
por: Vinay, Dass S., et al.
Publicado: (2012) -
Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137
por: Li, Shi-Yan, et al.
Publicado: (2013) -
Contributions of Costimulatory Molecule CD137 in Endothelial Cells
por: Yuan, Wei, et al.
Publicado: (2021) -
4-1BB (CD137) in anticancer chimeras
por: Melero, Ignacio, et al.
Publicado: (2020)